Harrow (HROW) Cash from Operations Growth (3y) (2013 - 2026)
Harrow (HROW) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 34.90% |
| 3 | Zoetis | 32.71 Bn | 30.77 Bn | 1.62 Bn | -9.94% |
| 4 | Takeda Pharmaceutical | 27.62 Bn | 23.56 Bn | 4.39 Bn | -10.80% |
| 5 | United Therapeutics | 23.18 Bn | 21.03 Bn | 648.10 Mn | 7.32% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | -26.33% |
| 8 | Neurocrine Biosciences | 17.80 Bn | 16.48 Bn | 800.70 Mn | 46.81% |
| 9 | Elanco Animal Health | 12.67 Bn | 12.24 Bn | 785.00 Mn | 27.85% |
| 10 | Harrow | 1.41 Bn | 1.31 Bn | 27.05 Mn | -3.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.06% |
| Dec 31, 2025 | 62.18% |
| Sep 30, 2025 | 248.86% |
| Jun 30, 2025 | -29.37% |
| Mar 31, 2025 | 172.97% |
| Dec 31, 2024 | -128.51% |
| Sep 30, 2024 | 50.69% |
| Jun 30, 2024 | -35.81% |
| Mar 31, 2024 | -51.00% |
| Dec 31, 2023 | 158.95% |
| Sep 30, 2023 | -34.86% |
| Jun 30, 2023 | 54.98% |
| Mar 31, 2023 | -146.26% |
| Dec 31, 2022 | -61.94% |
| Sep 30, 2022 | -80.26% |
| Jun 30, 2022 | 79.24% |
| Mar 31, 2022 | 38.47% |
| Dec 31, 2021 | -245.91% |
| Sep 30, 2021 | -103.50% |
| Jun 30, 2021 | 58.55% |